Research graph
References from Major Adverse Cardiovascular Events in Men with High-risk Localized or Metastatic Prostate Cancer Starting Long-term Hormone Therapy in the STAMPEDE Trial. Local targets link to admitted publications; unresolved targets remain external evidence.
Chemohormonal therapy in metastatic hormone-sensitive prostate cancer
10.1056/nejmoa1503747 · 2015 · External reference
Addition of docetaxel, Zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial
10.1016/s0140-6736(15)01037-5 · 2016 · External reference
Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer
10.1056/nejmoa1704174 · 2017 · External reference
Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial
10.1016/s0140-6736(18)32486-3 · 2018 · External reference
Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol
10.1016/s0140-6736(21)02437-5 · 2022 · External reference
Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol
10.1016/s1470-2045(23)00148-1 · 2023 · External reference
Enzalutamide with standard first-line therapy in metastatic prostate cancer
10.1056/nejmoa1903835 · 2019 · External reference
Arches: a randomized, phase 3 study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer
10.1200/jco.19.00799 · 2019 · External reference
Apalutamide for metastatic, castration-sensitive prostate cancer
10.1056/nejmoa1903307 · 2019 · External reference
Darolutamide and survival in metastatic, hormone-sensitive prostate cancer
10.1056/nejmoa2119115 · 2022 · External reference
Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design
10.1016/s0140-6736(22)00367-1 · 2022 · External reference
Cardiovascular events and androgen receptor signaling inhibitors in advanced prostate cancer: a systematic review and meta-analysis
10.1001/jamaoncol.2024.1549 · 2024 · External reference
Improving research for prostate cancer survivorship: a statement from the Survivorship Research in Prostate Cancer (SuRECaP) working group
10.1016/j.urolonc.2019.10.006 · 2020 · External reference
Major adverse cardiovascular event definitions used in observational analysis of administrative databases: a systematic review
10.1186/s12874-021-01440-5 · 2021 · External reference
Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: RTOG 85–31
10.1200/jco.2007.12.3752 · 2009 · External reference
Cardiovascular risk in men with prostate cancer: insights from the RADICAL PC study
10.1097/ju.0000000000000714 · 2020 · External reference
Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology
10.1161/circulationaha.109.192695 · 2010 · External reference
2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)
10.1093/eurheartj/ehac244 · 2022 · External reference
Cardiovascular disease risk assessment and multidisciplinary care in prostate cancer treatment with ADT: recommendations from the APMA PCCV expert network
10.1007/s00345-024-04852-2 · 2024 · External reference
SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europ
10.1093/eurheartj/ehab309 · 2021 · External reference
10.1093/eurheartj/ehab312
10.1093/eurheartj/ehab312 · External reference
Data resource profile: hospital episode statistics admitted patient care (HES APC)
10.1093/ije/dyx015 · 2017 · External reference
Data provenance and integrity of health-care systems data for clinical trials
10.1016/s2589-7500(22)00122-4 · 2022 · External reference
Fracture-related hospitalisations in newly diagnosed high-risk localised or metastatic hormone-sensitive prostate cancer: secondary analysis of the STAMPEDE phase 3 trials of docetaxel and zoledronic acid using healthcare systems data
10.1016/j.annonc.2025.07.005 · 2025 · External reference
Validity of acute cardiovascular outcome diagnoses recorded in European electronic health records: a systematic review
10.2147/clep.s265619 · 2020 · External reference
Completeness and diagnostic validity of recording acute myocardial infarction events in primary care, hospital care, disease registry, and national mortality records: cohort study
10.1136/bmj.f2350 · 2013 · External reference
Identification of heart failure hospitalization from NHS Digital data: comparison with expert adjudication
10.1002/ehf2.14669 · 2024 · External reference
Towards better clinical prediction models: seven steps for development and an ABCD for validation
10.1093/eurheartj/ehu207 · 2014 · External reference
Estimating and comparing time-dependent areas under receiver operating characteristic curves for censored event times with competing risks
10.1002/sim.5958 · 2013 · External reference
Cardiovascular toxicities of androgen deprivation therapy in Asian men with localized prostate cancer after curative radiotherapy: a registry-based observational study
2022 · External reference
Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer
10.1200/jco.2006.06.2497 · 2006 · External reference
Validation of Systematic Coronary Risk Evaluation 2 (SCORE2) and SCORE2-Older Persons in the EPIC-Norfolk prospective population cohort
10.1093/eurjpc/zwad318 · 2024 · External reference
Patient demographics and major adverse cardiovascular events after androgen deprivation therapy for prostate cancer
10.1155/2024/2988289 · 2024 · External reference
Cardiovascular mortality in patients with metastatic prostate cancer exposed to androgen deprivation therapy: a population-based study
10.1016/j.clgc.2014.12.003 · 2015 · External reference
Introduction to the analysis of survival data in the presence of competing risks
10.1161/circulationaha.115.017719 · 2016 · External reference
Prostate radiotherapy in newly diagnosed metastatic prostate cancer
10.1097/mou.0000000000000675 · 2019 · External reference
Incidental coronary arterial calcification for cardiovascular risk assessment in men with prostate cancer undergoing PET/CT imaging
10.1016/j.clgc.2024.01.014 · 2024 · External reference
Evaluating clinical tools to monitor cardiovascular risk in men with prostate cancer receiving hormone therapy
10.1200/op-25-00506 · 2025 · External reference
Which patients with metastatic hormone-sensitive prostate cancer (mHSPC) benefit more from androgen receptor pathway inhibitors (ARPIs)? STOPCAP meta-analyses of individual participant data (IPD)
10.1200/jco.2025.43.5_suppl.20 · 2025 · External reference
Unresolved reference
External reference
Cardiovascular safety of degarelix versus leuprolide in patients with prostate cancer: the primary results of the PRONOUNCE randomized trial
10.1161/circulationaha.121.056810 · 2021 · External reference
The value of real world evidence and pragmatic trials in advanced prostate cancer- insights from the electronic Prostate Cancer Australian and Asian Database
10.3389/fonc.2024.1494073 · 2024 · External reference
Association of patient comorbid conditions with cancer clinical trial participation
10.1001/jamaoncol.2018.5953 · 2019 · External reference
Contemporary accuracy of death certificates for coding prostate cancer as a cause of death: is reliance on death certification good enough? A comparison with blinded review by an independent cause of death evaluation committee
10.1038/bjc.2016.162 · 2016 · External reference
